Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.
Resistance to CCR5 antagonists can be driven by mutations in gp120. Sequences from 323 anti-CCR5 naive patients were analyzed for the presence of previously described in-vivo or in-vitro resistance mutations to CCR5 antagonists located in the V3 loop of gp120. The V3 loop region was rather polymorphic, and 7.3% of patients showed viruses with combinations of mutations in V3 loop previously described to be involved in maraviroc resistance, a licensed CCR5 antagonist.
Soulié
Cathia
C
UMPC Université Paris 06, Paris, France. cathia.soulie@psl.aphp.fr
Malet
Isabelle
I
Lambert-Niclot
Sidonie
S
Tubiana
Roland
R
Thévenin
Monique
M
Simon
Anne
A
Murphy
Robert
R
Katlama
Christine
C
Calvez
Vincent
V
Marcelin
Anne-Geneviève
AG
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000494:pharmacology; D024882:Drug Resistance, Viral / Q000235:genetics*; D005838:Genotype; D015699:HIV Envelope Protein gp120 / Q000235:genetics; D023581:HIV Fusion Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D000077592:Maraviroc; D009154:Mutation; D014230:Triazoles / Q000494:pharmacology
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D015699:HIV Envelope Protein gp120; D023581:HIV Fusion Inhibitors; D014230:Triazoles; C514793:gp120 protein, Human immunodeficiency virus 1; D000077592:Maraviroc